| Title |
A controlled trial of isoniazid therapy for action tremor in multiple sclerosis
|
|---|---|
| Published in |
Journal of Neurology, January 1987
|
| DOI | 10.1007/bf00314007 |
| Pubmed ID | |
| Authors |
C. B. Bozek, L. F. Kastrukoff, J. M. Wright, T. L. Perry, T. A. Larsen |
| Abstract |
Ten patients with clinically definite multiple sclerosis (MS) and action tremor were treated with isoniazid (INH) in a double-blind single crossover trial. The daily dose of INH administered during the 4-week treatment phase of the trial was determined by acetylator phenotype with slow acetylators receiving 12 mg/kg per day and rapid acetylators 20 mg/kg per day. Six of eight patients who completed the trial showed clinical improvement in the postural (alternating) tremor while on INH but the degree was minimal in all cases. Results of tremograms indicated that improvement also occurred in the intentional (synchronous) component of three patients while on INH, but this did not achieve statistical significance. Cerebrospinal fluid (CSF) levels of gamma-aminobutyric acid (GABA) homocarnosine and ornithine were markedly elevated with INH therapy (providing evidence for substantial inhibition of GABA aminotransferase activity and increase in GABA in the CNS), but no correlation was found between the degree of GABA elevation in the CSF and the clinical response. Side effects were minimal and well tolerated. Although INH appears to have a limited therapeutic role, a trial is warranted in MS patients with postural tremor. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 13% |
| Student > Doctoral Student | 2 | 9% |
| Unspecified | 2 | 9% |
| Professor | 2 | 9% |
| Researcher | 2 | 9% |
| Other | 4 | 17% |
| Unknown | 8 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 22% |
| Unspecified | 2 | 9% |
| Agricultural and Biological Sciences | 2 | 9% |
| Physics and Astronomy | 2 | 9% |
| Neuroscience | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 8 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#3,276,851
of 22,818,766 outputs
Outputs from Journal of Neurology
#819
of 4,475 outputs
Outputs of similar age
#1,554
of 45,105 outputs
Outputs of similar age from Journal of Neurology
#1
of 8 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,475 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 45,105 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them